| Autor: |
Barbar, Bruna, Mathieson, Campbell, Boot, Chris, Quinton, Richard, James, Andy, Perros, Petros, Pearce, Simon, Napier, Catherine, Gan, Earn, Mitchell, Anna, Mamoojee, Yaasir H. |
| Předmět: |
|
| Zdroj: |
Clinical Endocrinology; Dec2023, Vol. 99 Issue 6, p515-516, 2p |
| Abstrakt: |
Keywords: adrenal axis; cortisol; pituitary disease; synacthen test EN adrenal axis cortisol pituitary disease synacthen test 515 516 2 11/06/23 20231201 NES 231201 Adrenal insufficiency (AI) can be a life-threatening disease, which is why patients at risk of having secondary AI due to pituitary disease and/or its management typically undergo periodic evaluation with dynamic testing. Currently, a proportion of patients being weaned off immunosuppressive glucocorticoid therapy undergo SST, after suspending glucocorticoids for 24 h, to confirm recovery of the HPA axis.[3] If similar basal serum cortisol thresholds could be determined for the increasing number of patients at risk of iatrogenic secondary AI due to glucocorticoids prescribed as disease-modifying agents, then even greater resource savings could be implemented without any adverse impact on patient safety. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text